Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lispro SC
Lispro · 1 trial · 1 indication
Primary outcome measure is based on the PK area under the concentration curve from 0 to infinity with a measurable concentration.
| Arm | Type | Description |
|---|---|---|
| Part A: Lispro (A) | EXPERIMENTAL | Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods. |
| Part A: Lispro (B) | EXPERIMENTAL | Formulation B: Single dose of lispro administered SC in one of five periods. |
| Part A: Lispro (C) | EXPERIMENTAL | Formulation C: Single dose of lispro administered SC in one of five periods. |
| Part A: Lispro (D) | EXPERIMENTAL | Formulation D: Single dose of lispro administered SC in one of five periods. |
| Part A: Lispro (Reference) | EXPERIMENTAL | Reference formulation: Single dose of lispro administered SC in one of five periods. |
| Part B: Lispro | EXPERIMENTAL | Formulation selected from Part A. Single dose of lispro administered SC in one of four periods. |
| Name | Type | Description |
|---|---|---|
| Lispro | DRUG | Administered SC |
Inclusion Criteria: \- Overtly healthy males or females (non-childbearing potential and with absent cyclical hormonal changes), as determined by medical history and physical examination Exclusion Criteria: \- Have a fasting plasma glucose less than or equal to (≤) 4.0 millimole per liter (mmol/L)...
Lispro is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being evaluated in a clinical trial to assess its effects in healthy participants.
The molecular target of Lispro has not been disclosed. The drug is a small molecule in early-stage clinical development, and its specific mechanism of action is not publicly available at this time.
Lispro is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug in healthy volunteers.
Lispro is in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The drug is being studied in a Phase 1 trial involving healthy participants.
Lispro is being studied in a Phase 1 clinical trial with the identifier NCT02293551. This trial, titled 'A Study of Lispro Formulations in Healthy Participants,' has been completed and enrolled 54 participants in Singapore.
Yes, Lispro is also known as Lispro SC. Both names refer to the same investigational drug being developed by Eli Lilly and Company. The drug is currently in Phase 1 clinical trials for healthy volunteers.